{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alphagan+P",
    "query": {
      "intervention": "Alphagan P"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T15:58:32.289Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00440141",
      "title": "Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "latanoprost 0.005% eye drops and brimonidine 0.1% eye drops",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-07",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2008-01-02",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440141"
    },
    {
      "nct_id": "NCT03450629",
      "title": "Evaluation of Safety and Efficacy of PDP-716",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brimonidine Tartrate Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharma Advanced Research Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 682,
      "start_date": "2018-09-13",
      "completion_date": "2020-12-01",
      "has_results": true,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 47,
      "location_summary": "Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 37 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03450629"
    },
    {
      "nct_id": "NCT01144494",
      "title": "Aqueous Humor Dynamics and Brimonidine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Intraocular Pressure"
      ],
      "interventions": [
        {
          "name": "Brimonidine",
          "type": "DRUG"
        },
        {
          "name": "Artificial tears",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2010-08-01",
      "completion_date": "2011-10-01",
      "has_results": true,
      "last_update_posted_date": "2023-11-28",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01144494"
    },
    {
      "nct_id": "NCT02975557",
      "title": "Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye",
        "Ocular Graft vs Host Disease",
        "Meibomian Gland Dysfunction"
      ],
      "interventions": [
        {
          "name": "Brimonidine 0.15%",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine 0.075%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sandeep Jain, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-05",
      "completion_date": "2017-04-13",
      "has_results": true,
      "last_update_posted_date": "2019-11-08",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02975557"
    },
    {
      "nct_id": "NCT03825081",
      "title": "Pilocarpine and Brimonidine in Patients With Monofocal Lenses",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Presbyopia",
        "Pseudophakia"
      ],
      "interventions": [
        {
          "name": "Brimonidine, pilocarpine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2019-01-21",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-01-31",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03825081"
    },
    {
      "nct_id": "NCT00675207",
      "title": "Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brimonidine purite 0.15%",
          "type": "DRUG"
        },
        {
          "name": "Dorzolamide 2%",
          "type": "DRUG"
        },
        {
          "name": "Brinzolamide 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern Ophthalmic Institute S.C.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "41 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "41 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2006-01",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2008-05-08",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 1,
      "location_summary": "Glenview, Illinois",
      "locations": [
        {
          "city": "Glenview",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675207"
    },
    {
      "nct_id": "NCT00457795",
      "title": "24-hour IOP-lowering Effect of Brimonidine 0.1%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "brimonidine 0.1% (Alphagan® P)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2006-12",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2011-11-24",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00457795"
    },
    {
      "nct_id": "NCT01525173",
      "title": "A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "0.1% brimonidine tartrate ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "0.01% bimatoprost ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "0.2% hypromellose lubricant eye drops",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2012-01",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 1,
      "location_summary": "Deerfield Beach, Florida",
      "locations": [
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525173"
    },
    {
      "nct_id": "NCT00121147",
      "title": "Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension",
        "Pseudoexfoliation Syndrome"
      ],
      "interventions": [
        {
          "name": "Travatan",
          "type": "DRUG"
        },
        {
          "name": "Azopt",
          "type": "DRUG"
        },
        {
          "name": "Alphagan P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hermann Eye Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2003-09",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2006-02-24",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121147"
    },
    {
      "nct_id": "NCT00413751",
      "title": "Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter Reed Army Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-12-20",
      "last_synced_at": "2026-09-06T15:58:32.289Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413751"
    }
  ]
}